Kairasp Noshirwani, MD
Gastroenterology · Las Cruces, NMNPI 1427038967
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 499 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 24.7% of the total. Among gastroenterology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Pfizer$878
- Takeda Pharmaceuticals U.S.A., Inc.$560
- Gilead$438
- plus $2K from 23 others
What the payments were for
- Food & beverage$9,85097%
- Gifts$2763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $2,502 |
| Johnson & Johnson | 105 | $2,003 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 82 | $1,613 |
| Pfizer | 49 | $878 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $560 |
| Gilead | 22 | $438 |
| Madrigal Pharmaceuticals | 8 | $320 |
| Braintree Laboratories, Inc. | 4 | $276 |
| Bristol Myers Squibb | 15 | $269 |
| Phathom Pharmaceuticals, Inc. | 8 | $219 |
| Nestle Healthcare Nutrition Inc. | 11 | $186 |
| Intercept Pharmaceuticals, Inc. | 10 | $154 |
| Ardelyx, Inc. | 6 | $137 |
| Ipsen Biopharmaceuticals, Inc | 6 | $120 |
| Novo Nordisk | 1 | $81 |
| Merck | 4 | $63 |
| Fresenius Kabi USA, LLC | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Olympus America Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Mauna Kea Technologies, Inc. | 1 | $24 |
| Organon | 1 | $22 |
| Boston Scientific | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $15 |
| Ambu Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,126 in reported general payments places this provider in the 90th percentile of 81 gastroenterology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 19 | $223,808 |
| ZenpepLipase/Protease/Amylase | 17 | $74,299 |
| XifaxanRifaximin | 13 | $42,419 |
| LinzessLinaclotide | 36 | $30,032 |
| Mesalamine | 31 | $18,225 |
| Budesonide EcBudesonide | 20 | $5,342 |
| Budesonide DrBudesonide | 30 | $5,086 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 236 | $4,143 |
| Omeprazole | 261 | $3,998 |
| Colestipol Hcl | 68 | $3,763 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 177 | $3,178 |
| Ursodiol | 23 | $2,481 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 13 | $1,902 |
| Famotidine | 81 | $1,337 |
| Pantoprazole Sodium | 102 | $1,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $2,502 | $253,84055 claims |
| Aimmune Therapeutics, Inc.Zenpep | $33 | $74,29917 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $1,613 | $44,32126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 gastroenterology providers in New Mexico.
Other gastroenterology in Las Cruces
- Jean-Pierre ReinholdLas Cruces$79K
- Thomas NattakomLas Cruces$7K
- Prasad PodilaLas Cruces$3K
- Antoine JakicheAlbuquerque$108K
- Fazia MirAlbuquerque$98K
- Christopher ChangAlbuquerque$51K
- Stuart WeismanAlbuquerque$19K
- Denis McCarthyAlbuquerque$17K
- Andrei GasicAlbuquerque$9K
- Daniel BujandaSanta Fe$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.